2seventy Bio, Inc.
https://www.2seventybio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From 2seventy Bio, Inc.
ASGCT Late Breakers: Pfizer’s Duchenne Results Underwhelm As Next-Gen Approaches Emerge
The congress’s late breakers highlight progress across cell and gene platforms and diseases, and Duchenne is in the spotlight as Sarepta’s SRP-9001 could soon gain accelerated approval.
Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.
Finance Watch: Summit Raises $500m For Shift From Anti-Infectives To Oncology
Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.
BMS's Abecma Faces J&J Threat Despite Pivotal Success In Earlier Myeloma Setting
The US major’s CAR-T therapy is likely to win a label expansion to the large third-line-plus myeloma setting following positive Phase III data but a rival candidate from J&J could nab more of the market.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice